The publication of University of Health Sciences Istanbul Sisli Hamidiye Etfal Application and Research Center.


Online article submission system has been turned over to eJManager. We kindly request you to submit your current article or new articles via eJManager system

          VOLUME 43 / ISSUE 1


The Journal is Indexed in


2 - Evaluation of efficacy of premix 25% insulin lispro protamine/lispro and premix 50% insulin lispro protamine/lispro on metabolic control in diabetic patients

Emine Şatır, Sema Uçak, Okcan Basat, Yüksel Altuntaş

Objective: We aimed to evaluate the effectiveness of single, two or three additive doses of premixed insulin lispro %25 or three doses of premixed insulin lispro %50 to existing OAD treatments, on HbA1C levels in Type II Diabetics with poor glycemic control. Materials and Methods: 112 patients with Type II DM with HbA1c levels >%7, despite using one or more OAD, and 29 patients with HbA1c levels >%7, despite using premixed insulin lispro %25 and %75 insulin lispro protamin suspension twice a day, and/or one or more OAD, were included in our study. Injectable premixed insulin lispro %25 twice a day was prescribed to patients, whose blood glucose levels didn’t regulate at the end of the 3rd month with additive premixed insulin lispro %25 to their existing OAD treatment. At the end of the 6th month, the patients with still unregulated blood glucose levels had premixed insulin lispro %25 or premixed insulin lispro %50 three times a day. The HbA1c levels were checked at 3, 6, and 9th months and compared with the basal levels. Results: %25 of the patients using premixed insulin lispro %25 once a day, 47.5% of the patients using it twice a day, and 77% of the patients using premixed insulin lispro %25 three times a day reached to the HbA1c <7% target levels to maintain American Diabetes Association’s glycemic control. 53.6% of the patients using premixed insulin lispro %25 three times a day, and 71.4% of the patients using premixed insulin lispro %50 reached to HbA1c <7% target levels. Conclusion: Our study can be an example model for treatments in which single dosage of premixed insulin lispro 25% can be started and the dose can be titrated and the treatment condensed, until the glycemic targets are reached. Furthermore, our study resulted that with premixed insulin lispro %50 three times a day, we can reach to the glycemic target levels in patients with large fluctuations in postprandial blood glucose levels and in patients with severe chronic hyperglycemia and high HbA1c levels with further insulin deficiency.

Keywords: Glycemic control, postprandial hyperglycemia, premixed insulin lispro %25, premixed insulin lispro %50, HbA1c

To read full article click


Home Page       Editorial       Editorial Board       Advisory Board       Information for Authors       Contact       Archive

Copyright ® 2011 Sisli Etfal Hastanesi Tıp Bülteni